Literature DB >> 19458556

The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.

Kari Chansky1, Jean-Paul Sculier, John J Crowley, Dori Giroux, Jan Van Meerbeeck, Peter Goldstraw.   

Abstract

PURPOSE: To assess the impact of cell type, age, and gender in addition to pathologic tumor, node, metastasis (TNM) stage in surgically managed stage I-IIIA non-small cell lung cancer (NSCLC) cases from the international staging database of the International Association for the Study of Lung Cancer.
MATERIAL AND METHODS: From the 67,725 cases of NSCLC submitted to the staging database, 9137 surgically managed cases were selected for which all the following variables were available: pathologic stage, age, gender, and specific histologic cell type. Performance status and smoking history were examined in subsets. Methods used were Cox proportional hazards regression and recursive partitioning and amalgamation (RPA) analyses.
RESULTS: Pathologic TNM stage, age, and gender were all independently prognostic for survival. The bronchioloalveolar carcinoma (BAC) subtype had superior survival over other cell types despite the potential for heterogeneity in this group. Adjusted comparisons revealed a small survival advantage for squamous cell carcinomas over non-BAC adenocarcinoma histology and also over large cell, though the effect appeared to be limited to the male patients. RPA revealed the importance of TNM stage primarily, and age was prognostic within stage groups. Cell type was not found to add prognostic value in the RPA analysis. Prognostic groups were formed based on the RPA output, and the prognostic value of these groupings was validated using the North American Surveillance, Epidemiology, and End Results Registries. Performance status and smoking history were prognostic in the subsets where data were available. Effects of other variable were not influenced by the inclusion of smoking status in regression models.
CONCLUSIONS: Age and gender are confirmed as important prognostic factors in surgically resected NSCLC. Cell type is less important, although the small population of cases classified as BAC have a survival advantage over other histologies, and there may be a small survival advantage for squamous cell carcinomas over non-BAC adenocarcinomas. Imbalances between stage, gender, and cell type at presentation may lead to a misleading result with respect to cell type in unadjusted analyses. Pathologic TNM category is the most important prognostic factor in this analysis.

Entities:  

Mesh:

Year:  2009        PMID: 19458556     DOI: 10.1097/JTO.0b013e3181a7716e

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  160 in total

1.  Lymphatic microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of the literature.

Authors:  Jun Wang; Kainan Li; Baocheng Wang; Jingwang Bi
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

2.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

3.  Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.

Authors:  Moubin Lin; David J Stewart; Margaret R Spitz; Michelle A T Hildebrandt; Charles Lu; Jie Lin; Jian Gu; Maosheng Huang; Scott M Lippman; Xifeng Wu
Journal:  Carcinogenesis       Date:  2011-04-22       Impact factor: 4.944

4.  Lung cancer staging: a physiological update.

Authors:  Michael Poullis; James McShane; Mathew Shaw; Steven Woolley; Michael Shackcloth; Richard Page; Neeraj Mediratta
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-03-14

5.  Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools.

Authors:  Alyson L Mahar; Carolyn Compton; Lisa M McShane; Susan Halabi; Hisao Asamura; Ramon Rami-Porta; Patti A Groome
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

6.  Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.

Authors:  Xiaofei Wang; Lin Gu; Ying Zhang; Daniel J Sargent; William Richards; Apar Kishor Ganti; Jeffery Crawford; Harvey Jay Cohen; Thomas Stinchcombe; Everett Vokes; Herbert Pang
Journal:  Lung Cancer       Date:  2015-08-18       Impact factor: 5.705

7.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

8.  Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.

Authors:  Ignacio I Wistuba; Carmen Behrens; Francesca Lombardi; Susanne Wagner; Junya Fujimoto; M Gabriela Raso; Lorenzo Spaggiari; Domenico Galetta; Robyn Riley; Elisha Hughes; Julia Reid; Zaina Sangale; Steven G Swisher; Neda Kalhor; Cesar A Moran; Alexander Gutin; Jerry S Lanchbury; Massimo Barberis; Edward S Kim
Journal:  Clin Cancer Res       Date:  2013-09-18       Impact factor: 12.531

9.  Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.

Authors:  Ming-Sound Tsao; Sophie Marguet; Gwénaël Le Teuff; Sylvie Lantuejoul; Frances A Shepherd; Lesley Seymour; Robert Kratzke; Stephen L Graziano; Helmut H Popper; Rafael Rosell; Jean-Yves Douillard; Thierry Le-Chevalier; Jean-Pierre Pignon; Jean-Charles Soria; Elisabeth M Brambilla
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

10.  Biostatistics: a toolkit for exploration, validation, and interpretation of clinical data.

Authors:  Jayawant N Mandrekar; Sumithra J Mandrekar
Journal:  J Thorac Oncol       Date:  2009-12       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.